Andrew Dervan is the founder of Cajal Neuroscience. Cajal Neuroscience has raised $96M in total funding. Latest round: Series A.
Andrew Dervan is the COO and co-founder of Cajal Neuroscience, a Seattle-based biotechnology company. Established in 2020, Cajal Neuroscience focuses on discovering and developing novel therapeutics for severe neurodegenerative conditions such as Alzheimer's and Parkinson's disease. The company utilizes a proprietary computational and experimental platform integrating human genetics, spatial multi-omics, and high-throughput microscopy to identify drug targets. In late 2022, Cajal Neuroscience announced a $96 million Series A funding round to scale its operations.
Full founder directory · Investor directory · Company funding database · Fundraising library